Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen
Executive Summary
Schering-Plough will study alternative dosing regimens for PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin) following approval of the hepatitis C combination therapy.
You may also be interested in...
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol
Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration
Roche will conduct a pilot study to assess the safety and tolerability of higher doses of Pegasys and Copegus in hepatitis C patients with poor prognostic factors as part of its postmarketing commitments